glp-1 receptor agonists and cardiovascular outcome trials an update

glp-1 receptor agonists and cardiovascular outcome trials an update The effects of beyond obesity type 2 diabetes: anti-atherosclerotic action Cardiovascular, mortality, and kidney outcomes

Name: glp-1 receptor agonists and cardiovascular outcome trials an update The effects of beyond obesity type 2 diabetes: anti-atherosclerotic action Cardiovascular, mortality, and kidney outcomes
Brand: www.rasophiles.fr
SKU: 9714973407
Price: 25.52 USD
Availability: InStock
Rating: 4.4707 (17 reviews)

SKU: 9714973407

4.5

EUR25.52 EUR69.52

Pay in 4 interest-free payments of $6.38 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 17 - Aug 22

Description

Our data was agree with Acikgoz et al

First, there were no significant differences within minimal/mild or moderate groups when given MSG as compared to placebo, but there was a significant LS mean difference for the severe group, where higher anxiety symptoms were reported during MSG challenge as compared to placebo ( t = 2.60, p = 0.03)